The advice I have from Dr Manuel Guzman is that it is THC that is the primary cancer killing cannabinoid.
Cannabigerol (CBG) also has been subject to relatively few scientific trials since its discovery in 1964. To date, there exist only limited number of papers available referencing the substance – a keyword search on PubMed yields fewer than 55 citations – which has been documented to possess anti-cancer, anti-inflammatory, analgesic, and anti-bacterial properties. According to a 2011 review published in the British Journal of Pharmacology, “[A] whole plant extract of a CBG-chemotype … would seem to offer an excellent, safe new antiseptic agent” for the treatment of multi-drug resistant bacteria. A more recent review published this year in the journal Pharmacology & Therapeutics further acknowledges that CBG and similar non-psychotropic cannabinoids “act at a wide range of pharmacological targets” and could potentially be utilized in the treatment of a wide range of central nervous system disorders, including epilepsy.
